Skip to content
FDAMedicines

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter

FDA recall n-amneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-inj ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Product may contain an inert fiber identified as polypropylene fibers from the IV bag
Text from FDA, unedited.

The recalled product

Bridgewater, NJ, Amneal Pharmaceutical LLC, is recalling two lots of Ropivacaine Hydrochloride Injection, USP, 500mg/100mL, Infusion bags to the hospital/user level as the products may contain an inert fiber identified as polypropylene fibers from the IV bag.
Text from FDA, unedited.

Company announcement, as FDA publishes it

FOR IMMEDIATE RELEASE – 04/18/2025 – Bridgewater, NJ, Amneal Pharmaceutical LLC , is recalling two lots of Ropivacaine Hydrochloride Injection, USP, 500mg/100mL, Infusion bags to the hospital/user level as the products may contain an inert fiber identified as polypropylene fibers from the IV bag.

Risk Statement: Introduction of polypropylene particulates into the epidural space (or inadvertent administration into the intrathecal space) may result in a variety of adverse events. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process to meningitis or potentially damage the spinal cord. Administered intrathecally, particulate matter could result in inflammation, hydrocephalus (water on the brain), which could lead to embolization and organ damage.

To date, Amneal Pharmaceuticals has received no reports of adverse events or injuries related to this recall.

The recalled product was distributed nationwide to wholesalers/distributors between the dates of 04/23/2024 to 11/8/2024 only.

The product is indicated for the production of local or regional anesthesia for surgery and or acute pain management and is packaged in 12x100mL Single Dose IV bags (NDC 70121-17343). The affected Ropivacaine Hydrochloride Injection, USP, 500mg/100mL, products are Lot AL240003 (exp 01/2026) and Lot AL240004 (exp 01/2026). No other Ropivacaine Hydrochloride Injection, USP lots are impacted.

Amneal is notifying its customers by UPS and is arranging for return of all recalled products. Wholesalers/distributors are asked to notify their hospital/ user customers of the recall and provide instruction to contact Amneal for the return of the recalled products to Amneal.

Hospitals/users with questions regarding this recall can contact Amneal Pharmaceuticals by: Phone: 833-582-0812 Monday-Friday, 8:00 am-5:00 pm, EST Fax: 631-983-2595 E-mail to: RopivacaineHCl-Recall@amneal.com

For Medical Inquiries or to report Adverse Events, or quality problems experienced with the use of this product, please contact Amneal Drug Safety by phone at 1-877-835-5472, Monday - Friday, 8:00 am – 6:00 pm, EST, or e-mail at DrugSafety@amneal.com .

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online : www.fda.gov/medwatch/report.htm

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration

Text from FDA (the company’s words), unedited.
  • Amneal Pharmaceuticals LLC. Ropivacaine Hydrochloride Injection, USP, 500mg/100mL IV bag

Source

Issued by
U.S. Food and Drug Administration
Firm
Amneal Pharmaceuticals LLC.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Amneal Pharmaceuticals LLC., Medicine: Ropivacaine, Month: April 2025, Week 2025-W16. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Product may contain an inert fiber identified as polypropylene fibers from the IV bag”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

Which products are included?

FDA states: “Bridgewater, NJ, Amneal Pharmaceutical LLC, is recalling two lots of Ropivacaine Hydrochloride Injection, USP, 500mg/100mL, Infusion bags to the hospital/user level as the products may contain an inert fiber identified as polypropylene fibers from the IV bag.”

When was this recall published?

FDA published this company announcement on April 18, 2025.

Other notices of Amneal Pharmaceuticals LLC.